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aollowing the Food andDrug Administration (FDA) approval
f the Cypher sirolimus-eluting stent (Cordis, Johnson &
ohnson, Miami, Florida) in 2003, a dramatic increase oc-
urred in the use of this device and the subsequently
pproved Taxus paclitaxel-eluting stent (Boston Scientific
orp., Natick, Massachusetts). By 2004, over 70% of
atients who underwent implantation of a coronary stent in
he National Heart, Lung, and Blood Institute Dynamic
egistry received a drug-eluting stent (1). Among the
ate-Breaking Clinical Trials in Interventional Cardiology
resented at the 54th Annual Scientific Sessions of the
merican College of Cardiology (ACC) in Orlando, Flor-
da, those reporting outcomes from drug-eluting stent trials
aptured the attention of attendees in a virtual drug-eluting
tent parade. For the first time, head-to-head comparisons
f the two FDA-approved stents were reported. Compari-
on of the use of sirolimus-eluting stents with coronary
rtery bypass grafting (CABG) and the results of a random-
zed comparison of a new sirolimus-type coating, ABT-578,
ith bare-metal stenting were reported. Use of the Taxus
tent in high-risk lesions was compared to bare-metal stents
BMS) in a randomized trial. The first randomized trial
esting the efficacy of the Cypher stent compared to BMS in
aphenous vein grafts was also reported. These and other
ate-breaking trials produced one of the most interesting
CC Scientific Sessions in recent years.
HE SIRTAX TRIAL
he objective of SIRTAX trial was to compare the safety
nd efficacy of the sirolimus-eluting Cypher stent with the
aclitaxel-eluting Taxus stent for percutaneous coronary
evascularization in all comers in a randomized trial (2).
ne-thousand and twelve patients treated at University
ospitals, Bern and Zurich, Switzerland, were randomized.
his study was conducted without industry support. Pa-
ients and outcome assessors were blinded. Patients with
oronary artery diameter 2.25 to 4.0 mm were included with
o limitation with respect to the number of lesions or vessels
reated. The primary end point was a composite of cardiac
eath, myocardial infarction (MI), or ischemia-driven target
essel revascularization (TVR) at nine months. Secondary
nd points included target lesion revascularization (TLR),
VR, and in-segment late luminal loss (stent plus 5-mm
orders) determined angiographically in a prespecified sub-
tudy of approximately 500 patients. Patient demographics,
linical presentation, and the extent of coronary disease were
uite similar in both Cypher- and Taxus-treated patients.From Interventional Cardiology, Emory University School of Medicine, and the
ardiac Catheterization Laboratory, Emory University Hospital, Atlanta, Georgia.lmost one-quarter of each group had ST-segment eleva-
ion myocardial infarction (STEMI), a similar percentage
ad troponin-positive acute coronary syndromes, and about
ne-half had stable angina. Patient groups were well
atched with respect to lesion characteristics, number of
esions, lesion length (approximately 19 mm), and proce-
ural details. Device and lesion success was 99% in both
roups. Dr. Stephan Windecker presented the primary end
oint of major adverse cardiac events (MACE) at nine
onths, which occurred in 6.2% of patients receiving a
ypher and 10.8% of patients treated with a Taxus stent
p  0.009). Target lesion revascularization was the only
omponent of the composite end point that was statistically
ifferent and it was lower in the Cypher-treated patients
4.8% vs. 8.3%, p  0.02). Rates of death, cardiac death,
nd MI were not significantly different.
In the angiographic substudy of 527 patients with over
00 lesions, in-segment late loss was significantly lower in
irolimus-eluting stents compared to paclitaxel-eluting
tents (0.19 mm vs. 0.32 mm, p  0.001) and in-segment
inary restenosis was lower (6.7% vs. 11.9%, p  0.02).
hese investigators concluded that sirolimus-eluting stents
ere superior to paclitaxel-eluting stents in prevention of
ACE in all comers at nine months owing primarily to a
eduction in angiographic restenosis and need for TLR.
HE REALITY TRIAL
he second randomized trial comparing the two FDA-
pproved drug-eluting stents (DES) recruited 1,353 pa-
ients in 90 centers in Europe, Asia, and Latin America (3).
he study was sponsored by Cordis, Johnson & Johnson.
atients included had lesions 50% in target vessels 2.75 to
.0 mm in diameter. The first lesion length was required to
e 15 mm and the second lesion 10 mm. Study patients
ad silent ischemia or stable or unstable angina. Patients
ith acute MI within 72 h, ostial lesions, unprotected left
ain, ejection fraction 25%, total occlusions, and in-stent
estenosis were excluded. The primary end point was in-
esion binary restenosis by quantitative coronary angiogra-
hy at eight months. Patients in the Cypher and Taxus
roups had similar baseline demographics. Approximately
8% were diabetic and 7% were insulin-dependent. Eighty-
ix percent in both groups had ACC/American Heart
ssociation (AHA) B2/C lesions; the mean lesion length
as 17 mm. There were no differences in procedural aspects;
esion success was achieved in 99% of patients. Over 90% of
atients underwent angiographic follow-up at eight months,
nd clinical follow-up was obtained in over 95%.
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atients receiving Cypher and 11.1% in Taxus patients (p
.31). No significant difference existed in death, cardiac
eath, MI, TLR, or MACE rates at eight months. Angio-
raphic parameters such as late loss favored Cypher; the
n-stent late loss for Cypher was 0.09 mm versus 0.31 mm
n the Taxus group (p  0.001). Significantly more stent
hromboses occurred in Taxus stents, 1.8% versus 0.4%,
han in Cypher (p  0.0196), and this represented the first
tudy to show a difference in safety between DES. All stent
hromboses occurred within 30 days of implantation. In
ontrast, only four stent thromboses were observed in over
,500 patients enrolled in TAXUS-I, -II, -IV, and -V, a
ate of approximately 0.3%. As was pointed out by Dr.
berhard Grube, the scheduled discussant for this late
reaking clinical trial, stent thrombosis was not a prespeci-
ed end point, and given the possibility of an alpha error, no
onclusions should be drawn.
HE ISAR-DIABETES TRIAL
his trial was a head-to-head comparison of Taxus versus
ypher stents in 250 diabetic patients randomized in two
erman centers (4). Funded by the German Heart Center,
he trial’s primary end point was late lumen loss; secondary
nd points were angiographic restenosis and need for TLR
uring a nine-month follow-up period. The study was
esigned to show the non-inferiority of the Taxus stent
ompared to the Cypher stent (an in-segment late loss
ifference 0.16 mm would indicate non-inferiority). Ap-
roximately one-third of patients were insulin-dependent,
nd mean lesion length was about 13 mm. Angiographic
ollow-up was obtained in 82% of patients. Late lumen loss
as 0.67 mm in Taxus patients and 0.43 mm in Cypher
atients. The late loss difference of 0.24 failed to show
on-inferiority of the paclitaxel stent. Dr. Adnan Kastrati
tated that the superiority of the sirolimus stent was dem-
nstrated at a p value of 0.002. Angiographic restenosis was
bserved in 16.5% of Taxus-treated patients and in 6.9% in
ypher patients (p  0.03). Target lesion revascularization
ccurred in 12% of Taxus patients and 6.4% of subjects
reated with Cypher (p  0.13). There was no difference in
he occurrence of death or MI between Cypher- and
axus-treated subjects. The three studies cited thus far
uggest that sirolimus-eluting stents have a more robust
nti-proliferative effect, but significantly better outcomes in
erms of clinical end points were reported only in the
IRTAX trial, and the difference was 3.5 TVRs per 100
atients treated.
HE TAXUS-V TRIAL
onducted in 66 U.S. centers, this study was a randomized
omparison of paclitaxel-eluting and bare-metal Express
tents (Boston Scientific Corp.) in complex anatomy (5).
oston Scientific Corp. was the sponsor. The TAXUS-V
tudy randomized 1,156 patients undergoing non-emergent ftent implantation of single lesions 10 mm to 46 mm in
ength with reference vessel diameter 2.25 to 4.0 mm.
essels were 2.5 mm in 39%; lesions were 26 mm long
n 26%; the mean stented segment was 28 mm. The primary
nd point, the rate of TVR for ischemia at nine months,
ccurred in 17.3% of BMS and 12.1% of Taxus stents (p 
.018) according to Dr. Gregg Stone. Binary restenosis was
resent in 33.9% of controls and 18.9% of subjects treated
ith Taxus (p  0.0001). There were no differences in
eath, MI, or stent thrombosis (0.7% vs. 0.7%) at nine
onths.
When the subgroup of patients treated with a 2.25-mm
tent was analyzed, TLR was significantly lower with Taxus
10.4% vs. 21.5%, p  0.03). The primary end point, TVR,
as not significantly reduced (24.7% in bare-metal group
ersus 16.0% in Taxus, p  0.16), but binary restenosis was
ignificantly lower with Taxus (31.2% vs. 49.4%, p  0.01).
o differences existed in rates of stent thrombosis, death,
I, or MACE at nine months.
In the subgroup of 379 patients who received multiple
tents, there was a higher rate of 30-day MACE in
axus-treated patients compared to the bare-metal stent
roup (8.3% vs. 3.3%, p  0.047). This was believed to be
elated to more side branch narrowing with Taxus stents
42.6% vs. 30.6%, p  0.03) and more frequently dimin-
shed Thrombolysis In Myocardial Infarction (TIMI) flow
hen a Taxus stent was added compared to when an
dditional bare-metal stent was implanted (41.9% vs.
8.6%, p  0.02). Whether this is related to the polymer
roducing thicker stent struts is uncertain. At nine months,
o differences were seen in rates of death, cardiac death, or
tent thrombosis, however, a marked reduction occurred in
VR (29.8% vs. 16.2%, p  0.002) and binary restenosis
57.8% vs. 27.2%, p  0.0001) with the use of Taxus stents.
HE ARTERIAL
EVASCULARIZATION THERAPIES STUDY (ARTS)-II
he ARTS-I trial was a randomized, multi-center, Euro-
ean study conducted in 1997 and 1998 in which 1,205
ultivessel disease patients were randomized to either
ABG or bare-metal stent implantation. At one year in the
RTS-I trial, there was no difference in death, stroke, or
I, but there were 17% more revascularizations and $2,973
ess cost with bare-metal stenting. The ARTS-II trial was a
ingle arm, 45-center, European study in which 607 mul-
ivessel disease patients received 3.7 sirolimus-eluting stents
er patient and outcomes were compared to the ARTS-I
rial (6). The main goal of the ARTS-II trial was to
emonstrate non-inferiority in clinical effectiveness and cost
ffectiveness of the sirolimus-eluting stent compared to the
RTS-I trial. The study was supported by Cordis, Johnson
nd Johnson. The primary end point of the ARTS-II trial
as the effectiveness of multivessel disease Cypher stenting
ompared to the ARTS-I–CABG trial group measured as
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AACE at one year was 10.4% compared to 11.6% in the
RTS-I (CABG) trial and 26.5% in the ARTS-I (percu-
aneous coronary intervention [PCI]) trial. Because
RTS-II patients had significantly higher risk than the
RTS-I trial patients, reflected by more diabetes, triple
essel disease, and other high risk features, Dr. Patrick
erruys and colleagues used a Bayesian statistical approach
o adjust for these differences. One-year MAACE adjusted
y this analysis was 8.1% for the ARTS-II trial versus 13.1%
or the ARTS-I (CABG) trial. Thus, despite a higher risk
rofile, the overall MAACE rates of the ARTS-II trial were
ower than the ARTS-I (PCI) and ARTS-I (CABG) trials,
nd adjustment for baseline differences accentuated this
nding. Further, the composite end point of death/
erebrovascular accident/MI was significantly lower for the
RTS-II trial compared to the ARTS-I (CABG) trial (p
.001). Re-intervention in the ARTS-I CABG trial at one
ear was significantly lower than the ARTS-II trial (4.1%
s. 8.5%, p  0.003). Although this was not a randomized
rial, the very favorable outcome of sirolimus-treated mul-
ivessel disease patients was reassuring and supported use of
his strategy for similar multivessel disease patients who are
uitable for drug-eluting stent implantation.
HE ENDEAVOR-II TRIAL
his was a randomized, double-blind, 72-center interna-
ional trial comparing the safety and efficacy of the ABT-
78–coated Driver cobalt-alloy stent (Medtronic Vascular,
anta Rosa, California) with the Driver bare-metal stent in
,197 patients who underwent stenting of a single de novo
esion (7). The trial was sponsored by Medtronic Vascular.
tent diameters were 2.25 to 3.5 mm and lesion length 14
o 27 mm. The primary end point was target vessel failure
cardiac death, MI, or TVR) at nine months. The initial
00 randomized patients were scheduled for angiographic
ollow-up at eight months.
Patient demographics and angiographic characteristics
ere not significantly different. Seventy-eight percent of
atients had ACC/AHA B2/C lesions; the mean lesion
ength was 14 mm, and the mean reference vessel diameter
as 2.75 mm. Lesion success was achieved in 99% of
atients. The primary end point, namely target vessel
ailure, occurred in 8.1% of patients receiving the ABT-
78–coated Endeavor stent (Medtronic Vascular) com-
ared to 15.4% in patients receiving a bare-metal stent (p 
.0005). The MACE at nine months was significantly lower
n Endeavor-treated patients (7.4% vs. 14.7%, p  0.0001).
arget lesion revascularization occurred less frequently in
ndeavor-treated patients (4.6% vs. 12.1%, p  0.0001),
ut there was no difference in death or MI. Six-hundred
atients underwent angiographic follow-up at eight months.
n-segment binary restenosis was significantly lower with
ndeavor (13.3% vs. 34.2%, p  0.0001) as was late loss
n-segment (0.36 mm vs. 0.71 mm, p  0.0001) and late coss in-stent (0.62 mm vs. 1.03 mm, p  0.0001). Stent
hrombosis rates were low (0.5% for Endeavor) and there
as no evidence of acquired malapposition. Dr. William
ijns noted the safety of Endeavor and its efficacy in
ubstantially reducing clinical restenosis and MACE com-
ared to the Driver bare-metal stent.
YPHER VERSUS BMS
N SAPHENOUS VEIN GRAFTS (SVG)
he first randomized trial comparing Cypher versus BMS
n de novo SVG lesions was reported by Vermeersch et al.
8) from Antwerp, Belgium. This was a prospective, ran-
omized, single-center study. The primary end point was
ate loss in-stent and in-segment at six-month follow-up
ngiography. Secondary end points were binary restenosis
nd clinical events. Vessel diameter was 2.5 to 4.5 mm.
atients with creatinine 3 mg/dl, those with total occlu-
ions, requirement for more than two stents, prior brachy-
herapy in the target vessel, or prior stent within 5 mm of
he target lesion were excluded. Distal protection was
trongly recommended and was utilized in 80% of patients.
eventy-five subjects were randomized either to Cypher or
MS. The mean graft age was 13.5 years. Patient demo-
raphics and lesion and graft location were similar in the
wo treatment groups. Lesion success was 100%. The
rimary end point, late loss, was significantly lower in
ypher-treated patients, both in-stent (0.43 mm vs. 0.93
m, p  0.0005) and in-segment (0.46 mm vs. 0.93 mm,
 0.0005). Binary restenosis occurred in 5% of Cypher-
reated patients and in 37% of patients receiving BMS (p 
.0005). Of 42 Cypher stents implanted, there were two
estenoses and no total occlusions compared to 15 resteno-
es and two total occlusions among 43 BMS. The MACE
t six months occurred in 16% of Cypher patients and in
7% of patients treated with BMS. The investigators
oncluded that the use of Cypher in SVGs appeared to be
afe and effective in reducing late loss and binary restenosis.
ES IN SMALL VESSELS
ong-term outcomes following sirolimus-eluting stenting
f vessels 2.7 mm in diameter were reported for almost
,000 patients gleaned from six multi-center trials by Leon
t al. (9). Compared to small vessel lesions treated with
MS, angiographic and clinical outcomes at eight to nine
onths were superior with Cypher for late loss (0.21 mm vs.
.81 mm, p  0.0001), restenosis (6.9% vs. 39.8%, p 
.0001), TLR (3.5% vs. 17.1%, p  0.0001), and MACE
6.4% vs. 19.4%, p 0.0001). Stent thrombosis in sirolimus
tent-treated patients occurred in 0.8% of cases, a rate not
ignificantly different from controls.
NPROTECTED LEFT MAIN STENTING
he use of DES in the treatment of unprotected left main
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June 7, 2005:4B–8B ACC 2005 Annual Session Highlightscientific Sessions. The Asian Multicenter Registry in a
rospective analysis of 138 patients reported that sirolimus
nd paclitaxel stents were equally effective, yielding reste-
osis rates of 3% or less, and TVR and MACE in only 1.5%
f cases at 12 months (10). Results from the Scripps Clinic,
owever, suggested a cautious approach was warranted. In
1 patients treated with Cypher stents, there were two
n-hospital acute stent thromboses and one cardiac death at
ve months; restenosis occurred in 30% of patients (11).
estenosis most often occurred at the circumflex ostium and
as frequently silent. In patients requiring repeat PCI, a
ignificant rate of re-restenosis was encountered. The inves-
igators recommended that the use of sirolimus-eluting
tents in unprotected left main coronary disease be reserved
or selected patients with mandated angiographic follow-up,
referably at three and nine months.
IFURCATIONS
ixed reactions were also reported with use of DES in
ifurcations. Among 178 patients treated with the crush
echnique, Ge et al. (12) reported stent thrombosis in 2.8%
nd MACE in 18% at six months . Outcomes were similar
or sirolimus- and paclitaxel-eluting stents. Using a more
onservative approach of stenting the main branch and
rovisional stenting of the side branch in 82 patients,
efevre et al. (13) noted no stent thromboses, and TVR
ccurred in only 2.5% of patients at seven months.
HRONIC TOTAL OCCLUSIONS (CTO)
lthough there has been no randomized, controlled trial of
ES in CTO, favorable outcome data from observational
tudies reported at the ACC 2005 Scientific Sessions
uggest improved efficacy compared to BMS. In 415 CTO
atients from the e-Cypher registry, six-month MACE was
.3% and TLR was 1.4% (14). In a prospective analysis of
80 patients with CTOs, in a multicenter Asian registry,
estenosis was reported in 2% and MACE in 2.3% of
ases (15). The rate of angiographic restudy was not stated.
utcomes with Cypher and Taxus were not significantly
ifferent. The combination of new wiring techniques to
mprove the initial success of CTO PCI (16) and DES to
uppress intimal proliferation and restenosis provides an
xciting and improved opportunity to palliate patients with
TOs and in many cases avoid the need for surgical
evascularization.
CUTE MI
ercutaneous intervention with stent implantation has be-
ome the preferred treatment for STEMI, especially in
igh-risk patients. Although a randomized trial of DES in
TEMI has not been performed, most of the reports of
heir use for this indication from the ACC 2005 Scientific
essions suggested that they are safe and effective. Among
12 consecutive STEMI patients reported from a single ienter, 51% received a sirolimus-eluting stent and the
emainder a bare metal stent (17). At six months, there were
o stent thromboses in patients receiving Cypher stents and
utcomes were better with respect to repeat intervention
1.4% vs. 7.8%, p 0.005), reinfarction (0.6% vs. 4.1%, p
.05), and MACE (3.4% vs. 16.3%, p  0.0001). In 216
TEMI patients treated at four Italian centers, 30-day
utcomes were similar with Cypher and Taxus, with mor-
ality at 2% and 3%, respectively, and stent thrombosis in
% and 2% of cases, respectively (18). However, in the
-Cypher registry among 171 patients who received 1
ypher stent within 24 h of infarction, stent thrombosis
ccurrence in 4.7% and TLR was higher at six months
ompared to patients without acute MI (8.2% vs. 1.8%, p 
.001) (19). A carefully conducted prospective trial of DES
n STEMI is needed.
N-STENT RESTENOSIS
lthough intravascular brachytherapy has been shown to be
afe and effective in preventing subsequent restenosis, re-
orts from the ACC 2005 Scientific Sessions suggest that
ES are the preferred strategy. Among 133 patients treated
ith brachytherapy at a single center, one-third eventually
equired re-intervention for failed brachytherapy (20). Io-
na et al. (21) in an observational trial of 124 patients
eported restenosis in 11% of subjects treated with Cypher
tents and in 30% following brachytherapy. Among 142
atients receiving Cypher stents for in-stent restenosis in
he e-Cypher registry, TLR was required in 15%; however,
tent thrombosis occurred in 3.5% of cases (22). In an Asian
ulticenter registry (23), the outcome of 260 patients
reated with DES was favorable for Cypher and Taxus
12-month TVR was 7.4% and 13.4%, respectively).
HE BARRICADE TRIAL
his randomized prospective study tested the safety and
fficacy of polytetrafluoroethylene (PTFE)-covered stents
ompared to BMS in SVGs (24). The primary end point
as angiographic restenosis at eight months. This report of
he first 243 patients randomized revealed balanced baseline
haracteristics and similar 30-day outcomes. However, at
ine months the outcomes were poorer for patients receiv-
ng the PTFE-covered stent with respect to MACE (33%
s. 21%, p  0.047). Angiographic restenosis occurred in
2.5% of PTFE-covered stents compared to 25.6% of BMS
p  0.39) and there was a trend toward more total
cclusions (20.3% vs. 10.5%, p  0.09). On the basis of
hese results, the trial was terminated. This PTFE-covered
tent remains available for treatment of coronary artery
erforations and can be lifesaving for this indication.
ONCLUSIONS
he ACC 2005 Scientific Sessions provided new insights
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ACC 2005 Annual Session Highlights June 7, 2005:4B–8Bead-to-head comparisons of the two FDA-approved prod-
cts were reported. The striking effectiveness of DES was
ffirmed in multiple but not in all anatomic subsets. The
uture of interventional cardiology has never been brighter,
nd DES are leading the parade.
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